The production of human papillomavirus type 16 L1 vaccine product fromEscherichia coliinclusion bodies
β Scribed by W. Lai; A. Middelberg
- Publisher
- Springer
- Year
- 2002
- Tongue
- English
- Weight
- 146 KB
- Volume
- 25
- Category
- Article
- ISSN
- 1615-7605
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
Publication of the International Union Against Cancer Publication ds I'Union Internationale Contre 18 Cancer
## Abstract The prevalence of HPV infection in Latin America is among the highest in the world. A quadrivalent (types 6/11/16/18) human papillomavirus L1 virusβlikeβparticle vaccine has been shown to be 95β100% effective in preventing HPV 6/11/16/18βrelated cervical and genital disease in women naΓ―
Sera from I 18 women of 33 to over 90 years of age, with or without a history of cervical squamous-cell carcinoma, were examined for the presence of antibodies to HPV-6b, HPV-I6 and HPV-18 LI, U, E4, and E7 gene products by the use of bacterially derived P-Gal fusion proteins and Western-blot analys